Feb 15, 2024

Embarking on a New Chapter:

Embarking on a New Chapter:

Embarking on a New Chapter:

Themison Celebrates Antler Investment and Innofounder Program Entry

Themison Celebrates Antler Investment and Innofounder Program Entry

Themison Celebrates Antler Investment and Innofounder Program Entry

We at Themison are excited to announce two transformative milestones in our journey: securing a €150K investment from Antler and gaining acceptance into the prestigious Innofounder program with an additional €100K funding. These achievements are a testament to our commitment to revolutionizing patient engagement in clinical trials.


Our collaboration with Antler began in September 2023, catalyzed by our shared vision to tackle the persistent challenge of high dropout rates in clinical trials. This partnership has been crucial in developing our platform, designed to enhance patient retention and accelerate the drug development process through innovative patient-centric approaches.


Being accepted into the Innofounder program, known for its support of startups with high growth potential and societal impact, marks another significant milestone for us. This recognition is not just an endorsement of our innovative approach but also provides us with valuable resources and mentorship to further our development.


Our platform leverages a behavioral algorithm and a customizable app to improve the clinical trial experience, targeting the root causes of patient attrition. This approach aims to streamline trial processes, enhance communication, and offer personalized support to reduce dropout rates significantly.


These milestones—securing funding from Antler and the Innofounder program—reaffirm our mission and strengthen our resolve to make clinical trials more patient-friendly and efficient. As we continue to build our platform and gear up for its first application in a clinical trial, we're more excited than ever about the future.


Together, we are not just envisioning a new era of patient engagement in clinical trials; we are actively building it. Stay tuned for more updates as we move forward on this promising journey, aiming to reshape the landscape of clinical trials for the better.


We at Themison are excited to announce two transformative milestones in our journey: securing a €150K investment from Antler and gaining acceptance into the prestigious Innofounder program with an additional €100K funding. These achievements are a testament to our commitment to revolutionizing patient engagement in clinical trials.


Our collaboration with Antler began in September 2023, catalyzed by our shared vision to tackle the persistent challenge of high dropout rates in clinical trials. This partnership has been crucial in developing our platform, designed to enhance patient retention and accelerate the drug development process through innovative patient-centric approaches.


Being accepted into the Innofounder program, known for its support of startups with high growth potential and societal impact, marks another significant milestone for us. This recognition is not just an endorsement of our innovative approach but also provides us with valuable resources and mentorship to further our development.


Our platform leverages a behavioral algorithm and a customizable app to improve the clinical trial experience, targeting the root causes of patient attrition. This approach aims to streamline trial processes, enhance communication, and offer personalized support to reduce dropout rates significantly.


These milestones—securing funding from Antler and the Innofounder program—reaffirm our mission and strengthen our resolve to make clinical trials more patient-friendly and efficient. As we continue to build our platform and gear up for its first application in a clinical trial, we're more excited than ever about the future.


Together, we are not just envisioning a new era of patient engagement in clinical trials; we are actively building it. Stay tuned for more updates as we move forward on this promising journey, aiming to reshape the landscape of clinical trials for the better.


Juan Miguel Lopez

Juan Miguel Lopez

Co-CEO & CCO

Subscribe to
Our Newsletter

Subscribe to
Our Newsletter

Subscribe to
Our Newsletter

Stay Informed, and Stay Ahead of the Curve with Our Exclusive Newsletter

Stay Informed, and Stay Ahead of the Curve with Our Exclusive Newsletter

Stay Informed, and Stay Ahead of the Curve with Our Exclusive Newsletter

Founded in 2023, Themison is a Danish health tech company revolutionizing patient engagement in clinical trials. We are open to collaboration and we welcome inquiries from potential business partners, investors, and talented individuals looking to join our team.

Copenhagen, Denmark

info@themison.com

Privacy Policy

Terms of Service

© 2024 by Themison Aps. All rights reserved.

Founded in 2023, Themison is a Danish health tech company revolutionizing patient engagement in clinical trials. We are open to collaboration and we welcome inquiries from potential business partners, investors, and talented individuals looking to join our team.

Copenhagen, Denmark

info@themison.com

© 2024 by Themison Aps. All rights reserved.

Founded in 2023, Themison is a Danish health tech company revolutionizing patient engagement in clinical trials. We are open to collaboration and we welcome inquiries from potential business partners, investors, and talented individuals looking to join our team.

Copenhagen, Denmark

info@themison.com

© 2024 by Themison Aps. All rights reserved.